Pathology: mGC or mGEJC - L1 - HER2 neg/PDL1 positive; mGC or mGEJC - L1 - HER2 negative; mGC or mGEJC - L1 - PDL1 positive;
mGC or mGEJC - L1 - HER2 neg/PDL1 positive | mGC or mGEJC - L1 - HER2 negative | mGC or mGEJC - L1 - PDL1 positive | ||||||
CheckMate 649 (PDL1 CPS>5), 2021 | CheckMate 649 (PDL1 CPS>1), 2021 | CheckMate 649, 2021 | KEYNOTE-062 (P vs C ; CPS>10), 2020 | KEYNOTE-062 (P vs C ; CPS>1), 2020 | KEYNOTE-062 (PC vs C ; CPS>1), 2020 | KEYNOTE-062 (PC vs C ; CPS>10), 2020 | ||
nivolumab plus SoC | 3 | T1 | T1 | T1 | ||||
pembrolizumab alone | 2 | T1 | T1 | |||||
pembrolizumab plus SoC | 2 | T1 | T1 | |||||
Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | |||
placebo plus SoC | 0 | T0 | T0 | T0 |